# overton (blogs) — RSS Amplifier Recent posts from the 2 feeds in the RSS Amplifier directory that cover overton. Page: Feed: --- ## [Lawmakers urge FDA to enact new China policies after 3 gene therapy deaths](https://www.biospace.com/policy/lawmakers-urge-fda-to-enact-new-china-policies-after-3-gene-therapy-deaths) _2026-08-21 · Gabrielle Masson · FDA News: Approvals, Adcomms, Complete Response Letters and Guidances_ Three fatalities occurring recently in China clinical trials have spurred two members of U.S. Congress to urge the FDA to enact new policies designed to protect American patients. ## [Regeneron wins FDA approval to challenge Ipsen for rare bone disease market](https://www.biospace.com/fda/regeneron-wins-fda-approval-to-challenge-ipsen-for-rare-bone-disease-market) _2026-08-20 · Nick Paul Taylor · FDA News: Approvals, Adcomms, Complete Response Letters and Guidances_ Regeneron’s Pasatru is the second fibrodysplasia ossificans progressiva drug approved in the U.S., following the 2023 approval of Ipsen’s Sohonos. ## [Ultragenyx bags first gene therapy approval as previously rejected Sanfilippo asset awaits decision](https://www.biospace.com/fda/ultragenyx-bags-first-gene-therapy-approval-as-previously-rejected-sanfilippo-asset-awaits-decision) _2026-08-20 · Nick Paul Taylor · FDA News: Approvals, Adcomms, Complete Response Letters and Guidances_ The accelerated greenlight for Ultragenyx’s gene therapy for glycogen storage disease has raised analyst expectations for approval of UX111, which the FDA rejected last summer and is currently reviewing for a second time. A decision is expected by mid-September. ## [Why pediatric rare oncology outperforms in a volatile biotech market](https://www.biospace.com/drug-development/opinion-why-pediatric-rare-oncology-outperforms-in-a-volatile-biotech-market) _2026-08-20 · Paul Romness · FDA News: Approvals, Adcomms, Complete Response Letters and Guidances_ Real progress happens where unmet medical need is greatest and patient impact can be clearly measured. Pediatric rare cancers exemplify these criteria and have therefore generated continued investment, even in a capital-constrained environment. ## [Trump's FDA pick Overton good for psychedelics, new pain meds but bad for vaccines: Analysts](https://www.biospace.com/fda/trumps-fda-pick-overton-good-for-psychedelics-new-pain-meds-but-bad-for-vaccines-analysts) _2026-08-19 · Heather McKenzie · FDA News: Approvals, Adcomms, Complete Response Letters and Guidances_ If confirmed by the Senate, Heidi Overton—officially revealed Wednesday as President Donald Trump’s choice for FDA commissioner—is expected to be a boon for developers of psychedelic therapeutics and non-opioid pain drugs, but could tow the party line on vaccines. ## [The Stranger I Already Knew](https://roxannebouchoverton.substack.com/p/the-stranger-i-already-knew) _2026-08-19 · Roxanne Bouché Overton · Roxanne Bouché Overton_ There are only a handful of afternoons ## [Trump picks White House aide Heidi Overton as FDA chief: Reports](https://www.biospace.com/fda/trump-picks-white-house-aide-heidi-overton-as-fda-chief-reports) _2026-08-19 · Annalee Armstrong · FDA News: Approvals, Adcomms, Complete Response Letters and Guidances_ If Heidi Overton clears the Senate nomination process, analysts say she will have a tough job ahead to “restore predictability” to an agency battered by layoffs and controversial policies. ## [Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more](https://www.biospace.com/fda/amylyxs-redemption-story-summits-survival-woes-definiums-anxiety-win-more) _2026-08-19 · Jef Akst · FDA News: Approvals, Adcomms, Complete Response Letters and Guidances_ Amylyx shares good news for its investigational GLP-1 blocker; Definium announces positive data for its LSD-based therapy in anxiety; Summit/Akeso’s ivonescimab shows degrading survival benefits; patients treated with Neurocrine’s Prader-Willi drug experience serious adverse events; and Eli Lilly cracks down on the black market for next-gen obesity asset retatrutide. ## [Capricor soars on potential FDA review extension, filing amendments](https://www.biospace.com/drug-development/capricor-soars-on-potential-fda-review-extension-filing-amendments) _2026-08-14 · Gabrielle Masson · FDA News: Approvals, Adcomms, Complete Response Letters and Guidances_ Capricor Therapeutics’ CEO Linda Marbán believes the FDA is willing to work with the biotech as the Aug. 22 deadline approaches for its Duchenne muscular dystrophy cell therapy deramiocel, with the biotech’s stock climbing 68% on the update. ## [BMS welcomes new multiple myeloma drug as generics batter current portfolio](https://www.biospace.com/fda/bms-welcomes-new-multiple-myeloma-drug-as-generics-batter-current-portfolio) _2026-08-14 · Tristan Manalac · FDA News: Approvals, Adcomms, Complete Response Letters and Guidances_ The FDA approves Zenbexus just as copycat competitors depress sales of Bristol Myers Squibb’s multiple myeloma drugs Pomalyst and Revlimid, which crashed 71% and 49% year-on-year, respectively, in the second quarter. ## [Marketplace for AI-Powered Professionals (Sponsored)](https://crawlproof.com/a/VyTNFKSZEPcG) _2026-08-14 · **Sponsored**_ Find professionals who use ChatGPT, Copilot, and Claude to deliver work faster. ## [Nascent US psychedelic therapy opportunity attracts overseas manufacturers](https://www.biospace.com/drug-development/nascent-us-psychedelic-therapy-opportunity-attracts-overseas-manufacturers) _2026-08-14 · Nick Paul Taylor · FDA News: Approvals, Adcomms, Complete Response Letters and Guidances_ Companies that manufacture MDMA and psilocybin for patients in other countries are looking to use their experience to access the potential U.S. market. ## [Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competition](https://www.biospace.com/drug-development/taiho-and-cullinans-zipalertinib-clears-phase-3-teeing-up-first-line-competition) _2026-08-13 · Gabrielle Masson · FDA News: Approvals, Adcomms, Complete Response Letters and Guidances_ Taiho Pharmaceutical and Cullinan Therapeutics’ cancer asset is already under FDA review in a later setting, with a decision expected by February. ## [What Photographers See That Other People Miss](https://roxannebouchoverton.substack.com/p/what-photographers-see-that-other) _2026-08-11 · Roxanne Bouché Overton · Roxanne Bouché Overton_ The human brain is an extraordinary editor. ## [The Lonliest Moment in Every Creative Life](https://roxannebouchoverton.substack.com/p/the-lonliest-moment-in-every-creative) _2026-08-04 · Roxanne Bouché Overton · Roxanne Bouché Overton_ There comes a moment ... ## [The Conversation Between Us](https://roxannebouchoverton.substack.com/p/the-conversation-between-us) _2026-07-28 · Roxanne Bouché Overton · Roxanne Bouché Overton_ Every creative life has a few unexpected gifts. ## [How Much of the World Are You Missing?](https://roxannebouchoverton.substack.com/p/how-much-of-the-world-are-you-missing) _2026-07-21 · Roxanne Bouché Overton · Roxanne Bouché Overton_ How Much of the World Are You Missing? ## [When Our Creation Leaves Us](https://roxannebouchoverton.substack.com/p/when-our-creation-leaves-us) _2026-07-14 · Roxanne Bouché Overton · Roxanne Bouché Overton_ Every creative act begins in solitude. ## [Every Photograph is About Time](https://roxannebouchoverton.substack.com/p/every-photograph-is-about-time) _2026-07-08 · Roxanne Bouché Overton · Roxanne Bouché Overton_ Most photographers think they photograph things ## [The Difference Between Looking and Seeing](https://roxannebouchoverton.substack.com/p/the-difference-between-looking-and) _2026-06-30 · Roxanne Bouché Overton · Roxanne Bouché Overton_ Most people assume looking and see are the same thing. ## [The Photograph I Remember](https://roxannebouchoverton.substack.com/p/the-photograph-i-remember) _2026-06-17 · Roxanne Bouché Overton · Roxanne Bouché Overton_ When I return from photographing, I often find myself looking at two different images. ## [Countdown to Getting Paid (Sponsored)](https://crawlproof.com/a/n7t7onm5ZDgM) _2026-06-17 · **Sponsored**_ Create a shareable wallet timer — deposits buy back time and pay debt down ## [We Learn to Photograph Things. Not Feeling.](https://roxannebouchoverton.substack.com/p/we-learn-to-photograph-things-not) _2026-06-16 · Roxanne Bouché Overton · Roxanne Bouché Overton_ Most photographers spend years learning to photograph things.